A detailed history of Pro Share Advisors LLC transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Pro Share Advisors LLC holds 5,358 shares of CRSP stock, worth $216,945. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,358
Previous 5,568 3.77%
Holding current value
$216,945
Previous $300,000 16.33%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$44.62 - $62.75 $9,370 - $13,177
-210 Reduced 3.77%
5,358 $251,000
Q2 2024

Aug 13, 2024

SELL
$51.17 - $68.18 $11,410 - $15,204
-223 Reduced 3.85%
5,568 $300,000
Q1 2024

May 08, 2024

BUY
$60.67 - $89.12 $32,155 - $47,233
530 Added 10.07%
5,791 $394,000
Q4 2023

Feb 14, 2024

SELL
$38.62 - $72.18 $2,394 - $4,475
-62 Reduced 1.16%
5,261 $329,000
Q3 2023

Nov 13, 2023

BUY
$45.39 - $59.0 $3,131 - $4,071
69 Added 1.31%
5,323 $241,000
Q2 2023

Aug 10, 2023

SELL
$43.47 - $67.77 $24,169 - $37,680
-556 Reduced 9.57%
5,254 $294,000
Q1 2023

May 25, 2023

BUY
$41.0 - $56.12 $238,210 - $326,057
5,810 New
5,810 $262,000
Q4 2022

Feb 02, 2023

SELL
$39.19 - $65.67 $5,525 - $9,259
-141 Reduced 1.81%
7,663 $311,000
Q3 2022

Nov 04, 2022

BUY
$61.1 - $83.78 $37,271 - $51,105
610 Added 8.48%
7,804 $510,000
Q2 2022

Aug 01, 2022

SELL
$43.23 - $73.83 $103,362 - $176,527
-2,391 Reduced 24.95%
7,194 $437,000
Q1 2022

May 10, 2022

SELL
$53.19 - $79.24 $63,349 - $94,374
-1,191 Reduced 11.05%
9,585 $602,000
Q4 2021

Feb 08, 2022

SELL
$70.09 - $111.29 $385,635 - $612,317
-5,502 Reduced 33.8%
10,776 $817,000
Q3 2021

Nov 12, 2021

BUY
$110.2 - $156.64 $293,572 - $417,288
2,664 Added 19.57%
16,278 $1.82 Million
Q2 2021

Aug 13, 2021

BUY
$100.84 - $161.89 $322,082 - $517,076
3,194 Added 30.65%
13,614 $2.2 Million
Q1 2021

May 14, 2021

SELL
$110.72 - $210.04 $53,477 - $101,449
-483 Reduced 4.43%
10,420 $1.27 Million
Q4 2020

Feb 09, 2021

SELL
$79.67 - $173.23 $32,266 - $70,158
-405 Reduced 3.58%
10,903 $1.67 Million
Q3 2020

Nov 13, 2020

BUY
$78.5 - $100.64 $122,224 - $156,696
1,557 Added 15.97%
11,308 $946,000
Q2 2020

Aug 03, 2020

BUY
$38.5 - $76.05 $59,906 - $118,333
1,556 Added 18.99%
9,751 $717,000
Q1 2020

May 15, 2020

SELL
$33.68 - $62.53 $156,982 - $291,452
-4,661 Reduced 36.26%
8,195 $348,000
Q4 2019

Feb 12, 2020

SELL
$36.68 - $73.13 $71,195 - $141,945
-1,941 Reduced 13.12%
12,856 $783,000
Q3 2019

Nov 12, 2019

SELL
$40.99 - $52.56 $26,438 - $33,901
-645 Reduced 4.18%
14,797 $607,000
Q2 2019

Aug 13, 2019

SELL
$35.45 - $48.2 $82,173 - $111,727
-2,318 Reduced 13.05%
15,442 $727,000
Q1 2019

May 15, 2019

BUY
$28.02 - $40.87 $2,661 - $3,882
95 Added 0.54%
17,760 $634,000
Q4 2018

Feb 14, 2019

SELL
$22.73 - $42.34 $39,527 - $73,629
-1,739 Reduced 8.96%
17,665 $505,000
Q3 2018

Nov 14, 2018

SELL
$44.35 - $65.71 $18,893 - $27,992
-426 Reduced 2.15%
19,404 $861,000
Q2 2018

Aug 13, 2018

SELL
$42.62 - $73.59 $61,671 - $106,484
-1,447 Reduced 6.8%
19,830 $1.17 Million
Q1 2018

May 14, 2018

SELL
$23.52 - $58.17 $19,356 - $47,873
-823 Reduced 3.72%
21,277 $973,000
Q4 2017

Feb 14, 2018

BUY
$16.95 - $23.48 $374,595 - $518,908
22,100
22,100 $519,000

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.16B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.